The “Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)” Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum
暂无分享,去创建一个
K. Thomas | Toshiyuki Yamamoto | H. Herfarth | L. Gould | A. Marzano | A. Ortega‐Loayza | A. Garg | L. Gerbens | J. Rick | Diana M. Chen | J. Dissemond | Marcia A. Friedman | A. Alavi | Debbie L Oakes | M. Friedman | Debbie L. Oakes
[1] S. Fei,et al. Molecular and cellular characterization of pyoderma gangrenosum: Implications for the use of gene expression. , 2021, The Journal of investigative dermatology.
[2] M. Mathur,et al. Pyoderma gangrenosum , 2020, Nature Reviews Disease Primers.
[3] Marlen Niederberger,et al. Delphi Technique in Health Sciences: A Map , 2020, Frontiers in Public Health.
[4] H. Williams,et al. Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology‐specific outcome taxonomy , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[5] W. Huang,et al. Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review * , 2020, The British journal of dermatology.
[6] H. Williams,et al. Navigating the landscape of core outcome set development in dermatology. , 2019, Journal of the American Academy of Dermatology.
[7] M. Rustin,et al. Pyoderma gangrenosum - a guide to diagnosis and management . , 2019, Clinical medicine.
[8] M. Suarez‐Almazor,et al. Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis , 2019, The Journal of Rheumatology.
[9] H. Williams,et al. Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative , 2018, The British journal of dermatology.
[10] Rosie Qin,et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts , 2018, JAMA dermatology.
[11] P. Williamson,et al. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery , 2017, Journal of clinical epidemiology.
[12] Jane M Blazeby,et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations , 2017, PLoS medicine.
[13] Angus G K McNair,et al. The COMET Handbook: version 1.0 , 2017, Trials.
[14] A. Gottlieb,et al. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes , 2017, BMJ Open.
[15] P. Williamson,et al. The use of qualitative methods to inform Delphi surveys in core outcome set development , 2016, Trials.
[16] T. Marhadour,et al. Anakinra Improves Pyoderma Gangrenosum in Psoriatic Arthritis: A Case Report. , 2015, Annals of internal medicine.
[17] M. Picardo,et al. Developing core outcome set for vitiligo clinical trials: international e‐Delphi consensus , 2015, Pigment cell & melanoma research.
[18] R. Sivamani,et al. Effective Strategies for the Management of Pyoderma Gangrenosum. , 2012, Advances in wound care.
[19] L. Naldi,et al. Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies , 2012, Dermatology.
[20] P. Glasziou,et al. Avoidable waste in the production and reporting of research evidence , 2009, The Lancet.
[21] H. Williams,et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. , 2015, The Journal of investigative dermatology.